Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone

NCT00079001 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00079001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00079001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2004
Completion date
October 31, 2014
Enrollment
645 (actual)
Sites
241

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, prostate cancer